1. The Purification of Luteal Phase Associated Protein (LPAP) from Human Peritoneal Fluid. Presented at Albany Medical Center Grand Rounds, March 26, 1987.
2. The Polycystic Ovary. Presented at George Washington Medical Center, May 9, 1989 for Journal Club resident presentation.
3. Muellerian Anomalies. Presented at George Washington Medical Center, June 6, 1990 at Grand Rounds.
4. The GnRH Antagonist, Nal-Glu, acutely blocks the LH surge but allows for resumption of folliculogenesis in normal women and in women undergoing hyperstimulation. EC Ditkoff, DL Cassidenti, RJ Paulson, MV Sauer, WL Paul, RA Lobo. Slide presentation at the Society for Gynecologic Investigation at the 38th Annual Meeting, San Antonio, Texas, March 21, 1991.
5. A Proposed Protocol for the use of the GnRH Antagonist (Nal-Glu) in IVF cycles and its comparison to the GnRH-Agonist (A). DL Cassidenti, MV Sauer, RJ Paulson, EC Ditkoff, and RA Lobo. Poster presentation at the Society for Gynecologic Investigation at the 38th Annual Meeting, San Antonio, Texas, March 21, 1991.
6. Time-Related Fluoroimmunoassay (FIA): A Better Clinical Indicator of LH Biological Activity. EC Ditkoff, JH Levin, WL Paul, RA Lobo: Slide presentation at the 47th American Fertility Society, Orlando, Fl, October 23, 1991.
7. Corticotropin-releasing factor decreases fasting insulin levels in patients with PCO. E.C. Ditkoff, K.L. Kornafel, E. Carmina, D. Shoupe, F.Z. Stanczyk, R.A. Lobo: Poster presentation at the Society for Gynecologic Investigation at the 39th Annual Meeting, San Antonio, Texas, March 20, 1992.
8. Ovarian Influence on adrenal androgen sensitivity and secretion in PCO, EC Ditkoff, F. Fruzzetti, L. Chang, F.Z. Stanczyk and R.A. Lobo: Poster presentation at the Society for Gynecologic Investigation at the 39th Annual Meeting, San Antonio, Texas, March 20, 1992.
9. Increased circulating levels of B-endorphin in PCO are not due to increased pituitary secretion. E. Carmina, EC Ditkoff, AG Vijod, A. Janni, and RA Lobo: Slide presentation at the Society for Gynecologic Investigation at the 39th Annual Meeting, San Antonio, Texas, March 19, 1992.
10. A Bimodal Effect of Estrogen on insulin resistance in postmenopausal women and a potential attenuating effect of progestin. SR Lindheim, EC Ditkoff, SC Presser, MA Vijod, FZ Stanczyk and RA Lobo: Slide presentation at the Pacific Coast Fertility Society, Palm Springs, CA, April 10, 1992.
11. Treatment of Tubal Factor Infertility in Elderly Women: Tubal surgery vs. In Vitro Fertilization. VS. Taleon, N. Husami, and EC Ditkoff: Slide presentation at the Fifth Annual Sloane Academic Assembly, New York, NY, June 3, 1993.
12. Sonographic Assessment of Catheter Placement During Embryo Transfer in an IVF Program. M Zieman, A Monteagudo, C Veit, and EC Ditkoff: Slide presentation at the Fifth Annual Sloane Academic Assembly, New York, NY, June 3, 1993.
13 .Norethindrone Acetate and Leuprolide Acetate (NETA + LA) Induces Down-Regulation More Efficiently than LA Alone in the Early Follicular Phase Prior to Controlled Ovarian Hyperstimulation During In Vitro Fertilization. EC Ditkoff, H. Groarke, M. Carter, P. Payakkamas, R. Prosser, F. Lebrun, N. Husami, G. Jagiello: Poster presentation at the American Fertility Society, San Antonio, Texas, November 8, 1994.
14. Controlled Ovarian Hyperstimulation (COH) is not influenced following ovarian suppression by the administration of Norethindrone Acetate (NETA) and Leuprolide Acetate (LA) during In Vitro Fertilization (IVF). EC Ditkoff, R. Zimmermann, H, Groarke, M. Carter, P. Payakkamas, R. Prosser, F. Lebrun, G. Jagiello: Poster presentation at the 42nd Annual Meeting for the Society for Gynecologic Investigation, Chicago, 111, March 23, 1994.
15. Ovarian cyst formation with prolonged ovarian suppression/ pituitary desensitization after early follicular phase GnRH agonist (GnRHa) administration is not associated with an adverse outcome in In Vitro Fertilization (IVF). EC Ditkoff, R. Zimmermann, H, Groarke, M. Carter, P. Payakkamas, G. Jagiello: Poster presentation at the Pacific Coast Fertility Society Annual Meeting in April, 1995.
16.The Clinical Utility of serum follicle stimulation hormone (FSH) and Luteinizing Hormone (LH) Measured by Fluoroimmunoassay (FIA) Compared to Radioimmunoassay (RIA) in Reproductive Endocrinology. EC. Ditkoff, M. Pesce, W.Hembree, MV Sauer. Poster presentation on April 19, 1996 at the Pacific Coast Fertility Society annual meeting.
17. Use of Anesthesia in Centers Associated With the Society of Assisted Reproduction Technology (SART). EC. Ditkoff, J. Plumb, A. Selick, MV. Sauer. Slide presentation on April 20, 1996 at the Pacific Coast Fertility Society annual meeting.
18. Poor responders to ovarian hyper stimulation may benefit from an attempt at natural cycle oocyte retrieval. SR. Lindheim, EC Ditkoff, A Vidali, M Zinger, MV Sauer. Slide presentation on May 31, 1996 at the IXth World Congress on Human Reproduction in conjunction with Vth World Conference on Fallopian Tube in Health and Disease in Philadelphia.
19. Oocyte and Pre-embryo Quality is not influenced Following Ovarian Suppression by the administration of Norethindrone Acetate (NETA) and Leuprolide Acetate (LA) During In Vitro Fertilization (IVF). EC Ditkoff, SR Lindheim, R Prosser, MV Sauer. Abstract accepted for poster presentation on November 5, 1996 at the 52nd annual meeting of the American Society for Reproductive Medicine in Boston.
20. Hydrosalpinges have a deleterious effect on endometrial receptivity. SR Lindheim, A Vidali, L Stadtmauer, MV Sauer, EC Ditkoff. Abstract accepted for poster presentation on November 5, 1996 at the 52nd annual meeting of the American Society for Reproductive Medicine in Boston.
21. Mitochondrial DNA obtained from ovarian stromal cells at the time of routine oocyte retrieval examined for presence of deletions. DM Lasser, EC Ditkoff, MV Saner. Poster presentation at the 45th annual meeting for the Society of Gynecologic Investigation, March 24th, 1997.
22. Measuring hCG in the absence of implantation using highly sensitive urinary assays for intact, beta-core, and free beta epitopes. PI Chang, RE Canfield, EC Ditkoff, JF O'Connor, MV Sauer. Poster presentation at the 1997 Pacific Coast Fertility Society (received TAP Pharmaceutical Best Poster Award).
23. Endometrial development prior to oocyte retrieval is not adversely effected by the administration of norethindrone acetate (NETA) with leuprolide acetate (LA) for ovarian suppression during in vitro fertilization (IVF). EC Ditkoff, P. Chang, MV Sauer. Poster presentation at 10th World Congress/In Vitro Fertilization, Vancouver, BC, May 29th, 1997.
24. Doppler Flow Studies are of limited value in Assessing Ovarian Viability following torsion. L Jackson and EC Ditkoff: Slide presentation at the 9th Sloane Academic Assembly, New York, NY, June 5th, 1977.
25. Doppler Blood Flow Studies are of Limited Value in Assessing Ovarian Viability Following Torsion. EC Ditkoff, L Jackson, I Timor, SR Lindheim. Abstract accepted as poster presentation at The American Society For Reproductive Medicine.
26. Screening Oocyte Donors for Cystic Fibrosis Using Multiplex PCR Amplification of CFTR Gene from Buccal Cell DNA. PI Chang, SR Lindheim, EC Ditkoff, and MV Sauer. Abstract accepted as poster presentation at The American Society For Reproductive Medicine.
27. Hysterosonography For Upper Genital Tract Screening In Recipients Of Donor Oocytes. SR Lindheim, PL Chang, R Zimmermann, EC Ditkoff, and MV Sauer. Abstract accepted as poster at The American Society For Reproductive Medicine.
Chapters:
1. Ditkoff EC, Sauer MV: hCG and Other Serum Markers. Management of Ectopic Pregnancy. Blackwell Science Inc. Submitted, in Press.
Publications:
1. Ditkoff, EC, Lobo, RA: Ovarian Stimulation. Current Opinion in Obstetrics & Gynecology, Vol 3, No 5 October 1991 p. 635-640.
2. Ditkoff, EC, Cassidenti, DL, Paulson, RJ, Sauer, MV, Paul, WL, Rivier, J, Yen, SSC, Lobo, RA: The GnRH Antagonist, Nal-Glu, Acutely Blocks the LH Surge but Allows for Resumption of Folliculogenesis in Normal Women. Am. J. Obstet Gynecol, Vol. 165, number 6 December 1991 p. 1811-17.
3. Ditkoff, EC, Crary, WG, Cristo, MC, Lobo, RA: Estrogen Improves Psychological Function in Asymptomatic Postmenopausal Women. Obstetrics & Gynecology, Vol. 78, Number 6, December 1991, p. 991-995.
4. Ditkoff, EC. Levin, JH, Paul, WL, and Lobo, RA: Time-resolved fluoroimmunoassay compared with radioimmunoassay of luteinizing hormone. Fertility And Sterility, Vol. 59 No. 2, February 1993, p. 305-310.
5. Cassidenti, DL, Sauer, MV, Paulson, RJ, Ditkoff, EC, Rivier, J, Yen, SSC, Lobo, RA: Comparison of the Use of the Gonadotropin-Releasing Hormone (GnRH) Antagonist (Nal-Glu) to GnRH Agonist (A) in In Vitro Fertilization (IVF) Cycles: A Preliminary Report. Am. J. Obstet Gynecol, Vol. 165, number 6 December 1991 p. 1806-10.
6. Carmina, E, Ditkoff, EC, Vijod, AG, Janni, A. Lobo, RA: Increased Circulating Levels of Immunoreactive B-Endorphin in Polycystic Ovary Syndrome is Not caused by Increased Pituitary Secretion. Am. J. Obstet Gynecol, Vol. 167, number 6 December 1992 p. 1819-24.
7. Lindheim, SR, Presser, SC, Ditkoff EC, Vijod MA, Stanczyk, FZ, Lobo, RA: A Possible Bimodal Effect of Estrogen on Insulin Sensitivity in Postmenopausal women and the Attenuating Effect of Added progestin. Fertility and Sterility, Vol. 60 No. October 1993, p. 664-667.
8. Statmauer, L, Ditkoff, EC, Session, D, Kelly, A: High dosages of gonadotropins are associated with poor pregnancy outcomes following in vitro fertilization-embryo transfer. Fertility and Sterility, Vol. 61 No 6, June 1994, p. 1058-1064.
9. Ditkoff, EC, Fruzzetti, R, Chang, L, Stanczyk, FZ, Lobo, RA: The Impact of Estrogen on Adrenal Androgen Sensitivity and Secretion in Polycystic Ovary Syndrome, J. Clin Endocrinol & Metab, 80 (2): Feb 1995, p. 603-7.
10. Stanczyk, FZ, Rosen, GF, Ditkoff, EC, Vijod, AG, Bernstein, L, Lobo, RA: Influence of estrogen on prostacyclin and thromboxane balance in postmenopausal women. Menopause, Vol. 2, No. 3, September 1995, p. 137-143.
11. Ditkoff/ EC, Sauer, MV: A combination of norethindrone acetate and leuprolide acetate blocks the GnRH agonistic response and minimizes cyst formation during ovarian hyperstimulation. Human Reproduction, Vol. 11 No. 5, May 1996 p. 1035-7.
12. Ditkoff, EC, Vidali, A, Sauer, MV: Pregnancy in a woman with Turner mosaicism following ovarian stimulation and in vitro fertilization. Journal of Assisted Reproduction and Genetics Vol. 13, No. 5, May 1996 p. 447-448.
13. Ditkoff, EC, Prosser, R, Zimmermann, RC, Lindheim, SR, Sauer, MV: The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation. Journal of Assisted Reproduction and Genetics Vol. 14, no.2, February 1997 p. 92-96.
14. Ditkoff, EC, Sauer, MV: Pregnancy in a woman with Familial Mediterranean Fever following ovarian stimulation and in vitro fertilization undergoing colchicine therapy. Journal of Assisted Reproduction and Genetics Vol. 13, No. 8, August 1996 p. 684- 685.
15. Ditkoff, EC, Plumb, J, Selick, A, Sauer, MV: Use of Anesthesia in Centers Associated With the Society of Assisted Reproduction Technology (SART). Journal of Assisted Reproduction and Genetics Vol. 14, No. 3. March 1997 p. 145-147.
16. Ditkoff, EC, Sauer, MV: The clinical utility of Fluoroimmunoassay and Radiometric assays in measuring FSH and LH of infertile women. Assisted Reproduction Reviews, May 1997.
17. Lindheim, SR, Witt, BW, Barad, DH, Ditkoff, EC, Sauer, MV: Short term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics Vol. 13, No. 9, September 1996 p. 745-747.
18. Lindheim, SR, EC, Vidali, A, Ditkoff, EC, Zinger, A, Sauer MV: Poor responders to ovarian hyperstimulation may benefit from an attempt at natural cycle oocyte retrieval. Journal of Assisted Reproduction and Genetics Vol. 14, No. 3, March 1997 p. 174-176.
19. Ditkoff, EC, Tucker, T, Longacre TA, Levine, RU, Lindheim, SR, Sauer, MV: Bilateral Serous Cystadenofibromas Clinically Simulating Hyper reaction Luteinalis Following Controlled Ovarian Hyperstimulation and In Vitro Fertilization. Journal of Assisted Reproduction and Genetics Vol. 14, No. 4, April 1997 p. 230-233.
20. Lindheim SR, Ditkoff EC, Zinger M, Sauer MV: Differences in Ovarian Stimulation Among Older and younger Women with a Diminished Gonadal Reserve. Journal of Assisted Reproduction and Genetics Vol. 14, No. 4, April 1997 p. 235-237.
21. Lindheim, SR, Yu S, Vidali, A, Statmauer, L, Ditkoff EC, Sauer, MV: Ovarian Hyperstimulation compounds the deleterious effects of hydrosalpinx on outcome during IVF-ET. Accepted to Assisted Reproduction Reviews.
22. Lindheim, SR, Chang P, Ditkoff, EC, Sauer, MV: Utility of Day 3 FSH and Estradiol in women with polycystic ovarian syndrome undergoing ovarian hyperstimulation and intrauterine insemination. Assisted Reproduction Reviews, Vol 7, Number 3, pp 137-138.
23. Lindheim, SR, Chang, P, Ditkoff EC, Sauer, MV: Increases in serum progesterone after human chorionic gonadotropin are not predictive of cycle outcome during IVF-ET. Assisted Reproduction Reviews, Vol 7, Number 3, pp 134-136.
24. Chang PL, Canfield RE, Ditkoff EC, 0'Connor JF, Sauer, MV: Measuring hCG in the absence of implantation using highly sensitive urinary assays for intact Beta-core, and free beta epitopes. Accepted for publication in Fertility and Sterility.
Past Administered and Funded Research Projects:
1. A Multicenter, randomized, double-blind, parallel group, dose ranging study to evaluate the safety of a cyclophasic hormone replacement therapy regimen of estradiol and norgestimate and its effect on endometrial histology, vaginal bleeding and metabolic parameters in postmenopausal women. Sponsored by RW Johnson. Principal Investigator
2. A Prospective, double-blind, randomized study of the safety and efficacy of lower doses of premarin and medroxyprogesterone acetate in postmenopausal women. Sponsored by Wyeth-Ayerst. Principal administrator/investigator
3. A triple-blind, randomized, placebo-controlled, parallel-group multicenter study to evaluate the efficacy and tolerability of the addition of alendronate sodium to ongoing hormone replacement therapy in the treatment of osteoporosis in postmenopausal women. Sponsored by Merck. Principal investigator.
4. Efficacy and safety comparison of estrogel (17B-estradiol in a topical gel) and the climara patch 12.5 sg cm system in the treatment of women with menopausal symptoms. Sponsored by CoVance. Principal investigator.
5. A 44 week randomized, double-blind, placebo controlled, multicenter study assessing the safety and efficacy of troglitazone in polycystic ovary syndrome. Sponsored by Parke Davis. Principal administrator/investigator.
Invited Lectures/Presentations: CME Lectures:
1. Grand Rounds for the Dept. of Ob/Gyn at Columbia Presbyterian Medical Center, April 13, 1995, In Vitro Fertilization and an Update in the Division of Assisted Reproduction.
2. Ob/Gyn Society of Roanoke Valley, Va. March 12, 1996, The role of Fosamax in the Management of the Menopause and Osteoporosis.
3. Grand Rounds at Passaic General Hospital, NJ. May 8, 1996, The Management of the Menopause.
4. Grand Rounds at Elizabeth General Medical Center-West, NJ. May 15, 1996. The role of Fosamax in the Management of the Menopause and Osteoporosis.
5. Grand Rounds at Morristown Hospital, NJ. June 13th, 1996. New Modalities in the Treatment of Osteoporosis in Menopausal Women.
6. Grand Rounds at Staten Island University Hospital, NY. January 29th, 1997. The Diagnosis and Treatment of Osteoporosis during the Menopause.
7. Grand Rounds at St. Vincent's Hospital, NY. January 31st, 1997. The Diagnosis and Treatment of Osteoporosis during the Menopause.
8. Speaker for the University of Southern California Medical School regarding the modern use of oral contraceptives: benefits and controversy.
9. Grand Rounds at White Plains General Hospital. June 5, 1997. The Diagnosis and Treatment of Osteoporosis during the Menopause.
10. Grand Rounds at the New York Methodist Hospital. June 30, 1997. The Diagnosis and Treatment of Osteoporosis during the Menopause.
11. Grand Rounds at Brookdale Medical Center. October 1, 1997. The role of NETA during ovulation induction during IVF.
Community Activities/Lectures:
1. Annual Resolve Meeting of Long Island, May 9, 1993, Various Infertility Drugs used in Assisted Reproductive Technologies.
2. Annual Resolve Meeting of New York City, May 2, 1993, at New York University "ask the experts panel regarding assisted reproductive technologies".
3. Monthly speaker for Resolve of New York City, October 1993, Ovulation Induction in Assisted Reproductive Technologies.
4. Annual Resolve Meeting of New York City, May 1, 1994, at New York Hospital, lecture on Ovulation Induction.
5. Annual Resolve Meeting of New York City, May 7, 1995, at Mount Sinai Hospital, "ask the experts panel regarding Assisted Reproductive Technologies".
6. Monthly speaker for Resolve of New York City, January 1995, Ovulation Induction in Assisted Reproductive Technologies.
7. Institution Coordinator at Columbia Presbyterian Medical Center for National Menopause Awareness Month, June 1996.
8. Annual Resolve Meeting of New York City, March 9, 1997, at New York University Medical Center, The Renaissance of GIFT: Is It Right for Me?
9. Annual Resolve Meeting for NYC's Brooklyn Conference, May 18, 1997, Age And Fertility Therapies.
10. Annual Resolve Meeting for NYC's Conference, 1998, Lecture on Fertility Medications.
11. Annual Resolve Meeting for NYC and NJ Conference, 2005, Lecture on When is the right time to proceed with Donor egg Treatment.
12. Scarsdale School District Health Advisory Committee Member from 2005-2007.
13. Annual Resolve Meeting for NY and NJ Familiy Building Conference, 2005, Discussion on donor ooctyes, October 23.
Columbia University Education Series Lectures:
1. Ob/Gyn medical student lectures at Columbia Presbyterian Medical Center monthly on "The Menopause" since 1992.
2. Ob/Gyn resident Reproductive Endocrinology lecture series at Columbia Presbyterian Medical Center from 1994-present.
3. Lecture for Dept. of Medicine house staff at Columbia
Presbyterian Medical Center on "Evaluation of Hirsutism" on 12/29/94.
4. Medical Endocrinology Lecture for division members at Columbia Presbyterian Medical Center on 3/26/96. Overview of IVF and ovulation induction protocols.
Consultant Meetings:
1. 1996 Wyeth Fosamax Consultant Meeting held in Chicago.
2. 1996 Metabolic Bone Disease Northeast Regional Consultants Meeting in New York City. (Sponsored by Merck)
3. October 8 1996 consultant meeting regarding hormone replacement therapy/cardiovascular disease in New York City.
4. October 25-27 1996 Parke-Davis Women's Health Marketing Advisory Meeting in New York City.
5. 1996 OB/GYN National Osteoporosis Consultants' Meeting in San Diego. (Sponsored by Merck)
6. 1997 Metabolic Bone Disease Northeast Regional Consultants Meeting in New York City. (Sponsored by Merck)
Current Practice Locations:
1. Advanced Fertility Services, 1625 Third Avenue, New York, NY, 10128
Tel: 212-369-8700 Fax: 212-722-5587
2. Advanced Fertility Services, 1990 Central Park Avenue, Yonkers, NY 10710
